Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DOC stock price vs STAG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STAG's multiple
Needs STAG P/E.
Implied fair value · at DOC's multiple
Needs Annual EPS, DOC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Healthpeak Properties, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
STAG Industrial, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DOC can sustain its current valuation despite slower growth, weaker margins, and high leverage versus STAG, then a cautious hold-or-selective buy makes sense because STAG-implied upside is large; if not, the data argue for caution because DOC’s fundamentals and balance sheet quality do not yet justify a full re-rating.
On a P/S basis, DOC trades at 5.0x versus STAG at 8.6x, while the provided STAG-implied price for DOC is $34.97 versus the current $20.53, implying 70.3% upside. However, the valuation signal is tempered by the fact that DOC also trades above the DCF range of $6.06-$8.20 and within its historical band of $18.48-$22.58, suggesting the market is not fully ignoring fundamental risk.
Supporting Metrics
